How to reconstitute Glutathione: mixing and storage
An antioxidant with mixed oral evidence and important risks from compounded injections.
Also called: GSH, Reduced L-glutathione, L-glutathione, GSSG, oxidized glutathione.
Antioxidant peptides · Endogenous thiol antioxidant; chemically a gamma-glutamyl tripeptide.
Comes as: Oral capsules and tablets, Liposomal or micellar oral formulations, Buccal lozenges and dissolving films, Topical lotion, Compounded injectable liquid or powder vials, Investigational nasal or nebulized formulations.
Mixed with: Forums report bacteriostatic water. This is not a universal diluent choice or a validated stability method..
Common vial sizes: 600, 1200, 1500 mg. Common water amounts: 1.5, 3, 6, 7.5 mL.
- Reported examples: 600 mg with 3 mL, 1,200 mg with 6 mL, or 1,500 mg with 7.5 mL. Each gives 200 mg/mL by arithmetic.
- Another report uses 600 mg with 1.5 mL, giving 400 mg/mL. Concentration does not establish a safe injection volume.
- Don't use these recipes for eye-surgery rinses or nasal trial products.
- Do not inject dietary-supplement-grade material. Clear appearance and a purity percentage cannot rule out endotoxin.
Before mixing: No universal temperature fits every formulation. Follow the product-specific storage and expiry instructions.
After mixing: A validated beyond-use date is formulation-specific. Forum mixing recipes do not establish sterility or shelf life.
Related to Glutathione
- NAD+ and precursors: NAD+ helps cells use energy; wellness injection benefits remain unproven.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- FDA reminds compounders not to use dietary supplement grade glutathione for injectables, FDA · 2026
- Find product information about medicines, Medicines and Healthcare products Regulatory Agency · MHRA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Advertising guidance for businesses involved with intravenous (IV) vitamin and related therapies: Complying with therapeutic goods advertising requirements, Therapeutic Goods Administration · 2023
- Pharmacy Compounding Advisory Committee Meeting June 8, 2022 Summary Minutes, FDA · 2022
- 30ml Reduced-Glutathione 200mg/ml (2020-11-13), Health Canada · 2020
- FDA highlights concerns with using dietary ingredient glutathione to compound sterile injectables, FDA · 2019
- BSS PLUS- balanced salt solution enriched with bicarbonate, dextrose, and glutathione kit, Alcon Laboratories, Inc. · DailyMed
- EU/3/06/361 - orphan designation for treatment of cystic fibrosis, European Medicines Agency
- Product information, Health Canada
- Validation of an HPLC-UV method for the analysis of glutathione and its impurities, FDA
- A cluster analysis of 466 patients demonstrates that glutathione supplementation could preferentially benefit advanced unstable cirrhosis phenotype rather than stable cirrhosis., Philips CA et al. · Frontiers in pharmacology · 2026
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.